Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVPH -- INNOVIVE Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (69)	2/20/2008 7:31:25 AM
From: rkrw	Read Replies (3) \| Respond to of 117

I dont think the compounds are crap. Tamibarotene approved in Japan, SPA secured, phase III started, seemed like close to no risk. 406, probably a decent compound, but never resonated. SKI-606 (WYE) apparently restarted and a very good compound and Sprycel dosing change to qd significantly improved its profile, so competition got much tougher recently. Still apparently trying to secure an spa for 406 but would have to find someone to take it on. Seems like if they closed up shop, kept tamibarotene, got it approved and then sold the company something decent could be salvaged. But with the stock tumbling, you just have to wonder what Paramount is thinking or doing if anything. All a bunch of slimy jokers. At least the recent 8K on employee retention shows they're going to try to sell the company. But could the writing have got any bigger before they made that decision? Maybe a PR that they hired a bank would stop whoever has been selling here to at least roll the dice and see what happens. Will Paramount step up and loan them a few $M to get it done? Or just let it fold and take the compounds for some other company they scraped together?